Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma

This study is testing a combination of laser heat therapy (LITT — laser interstitial thermal therapy) and a chemotherapy drug called lomustine (CCNU) for people with recurrent glioblastoma (a brain tumor that has come back after initial treatment). The laser treatment destroys tumor tissue with heat, and the chemotherapy may improve effectiveness. **You may be eligible if...** - You are 18 years or older - You have a confirmed diagnosis of glioblastoma that has returned or is growing after prior treatment - You have had prior standard radiation for glioblastoma - Your blood counts, liver, and kidney function meet required levels - Your general health and functional status are adequate (Karnofsky score of 50 or above) - You are able to swallow oral medication **You may NOT be eligible if...** - You are not a surgical candidate for laser ablation or biopsy - You have previously received a nitrosourea drug (such as lomustine, carmustine, or nimustine) - You have previously received bevacizumab (Avastin) - You had a recent major surgery within the past 4 weeks - You have evidence of significant active bleeding in the brain - You are pregnant or breastfeeding - You have a known allergy to lomustine Talk to your doctor to see if this trial is right for you.